Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound waves to calm the brain? new study tests ultrasound nerve stimulation

NCT ID NCT07283913

Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new device called ZenBud that uses ultrasound waves to stimulate the vagus nerve, a key nerve that controls relaxation and body functions. Researchers want to see if this method can safely change heart rate, brain activity, and mood in 30 healthy adults. The goal is to find out if this approach could one day help treat conditions like anxiety or depression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Participant is willing and able to give informed consent for participation in the study * Not currently taking any medications (except the contraceptive pill) * Aged 18 or over * Good general health * Able and willing to remove any piercings in the left ear * Able to abstain from exercise and fast from food for 12 hours before the second and third visit Exclusion Criteria * Current or past diagnosis of a major neurological, neurosurgical, or psychiatric disorder (including self-reported depression) * Inability to complete informed consent process * Personal history of cardiac arrhythmia * Diabetes * High blood pressure (\>140 mmHg systolic and/or \>90 mmHg diastolic) * Other significant medical condition (including cardiological disorders; specific details to be reviewed by the CI prior to inclusion) * Use of medication or recreational drugs that affect the nervous system in the past 3 months * Medication intake (such as beta-blockers, glucocorticoids, antidepressants, anti-inflammatory drugs) in the last 7 days - contraceptive medication in women is allowed * Currently pregnant or breastfeeding * Allergy to aquasonic gel or any of its components (propylene glycol, glycerin, isothiazolinones) * Participation in a research study in the last 3 months involving invasive procedures or an inconvenience allowance (required for all UoN FMHS UREC-approved studies) * BMI \< 18 kg/m² or \> 30 kg/m² * Excessive consumption of alcohol (\>2 alcoholic beverages/day) or tobacco (\>5 cigarettes/day) * Previous experience with stress tests * Known infection in the last 8 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy participants

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Neuromodulation Lab, Medical School, Queen's Medical Centre

    RECRUITING

    Nottingham, Nottinghamshire, NG7 2UH, United Kingdom

  • University of Nottingham

    NOT_YET_RECRUITING

    Nottingham, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.